ZEISS MyoCare Portfolio: Multicenter Clinical Trials Confirming Sustained Efficacy

The global prevalence of myopia and high myopia is rising, causing substantial health and financial burden. With strategies employed to prevent and slow the progression of myopia, it is crucial to establish efficacy from robust evaluations involving diverse ethnic groups, large samples, multiple locations, and long study periods. In two on-going, prospective, doublemasked, parallel-group, multicenter clinical trials across China and Europe, ZEISS MyoCare lenses are being evaluated for their effectiveness in slowing myopia.

Results from both trials were presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 4th to 8th in Salt Lake City, Utah. USA.

Comparison of one-year results between Asian and European populations indicated that ZEISS MyoCare was equally effective across different ethnicities.

TRIAL 1, ASIAN EYES (NCT05288335)

After two years of lens wear, compared to single vision (SV) lenses, progression of myopia was significantly slower with ZEISS MyoCare and ZEISS MyoCare S lenses. The difference in progression between MyoCare, MyoCare S and SV lenses for spherical equivalent refractive error (SE) and axial length (AL) were¹

TRIAL 2, EUROPEAN EYES (NCT05919654)

The one-year results of trial 2 are published in the journal Ophthalmic and Physiological Optics². In summary, after one-year of lens wear, slower progression was seen with ZEISS MyoCare as compared to SV lenses.

Additionally, fewer ZEISS MyoCare wearers exhibited fast progression (-0.50D or greater SE, and/or 0.20mm or greater AL elongation)³

Subjective ratings indicate that children adapted to ZEISS MyoCare lenses. Assessments after one week indicate that vision (including distance vision, near vision, vision during sports and daily activities) was overall rated as good to very good⁴.

Additionally, compared to past SE progression, ZEISS MyoCare was more effective than SV in slowing myopia, and this was irrespective of age of the individual⁵.

It is established that among all ethnicities, the East-Asian ethnicity has a higher prevalence and greater progression of myopia. If ethnicity influences onset and progression, does it also have implications for myopia control treatments? Comparison of data from Trial 1 (Asian children) and Trial 2 (European children) confirmed that 1-year progression was higher with SV lenses in Asian children. Despite this difference, ZEISS MyoCare lenses were effective in slowing myopia equally across both ethnicities. The absolute mean differences between MyoCare and SV for SE were 0.29D and 0.21D in Asian vs European children and 0.13mm in AL for both ethnicities⁶.

Due to myopia control treatments becoming standard of care, there are ethical and practical challenges in assigning children to SV groups in clinical trials. This necessitates a need to establish methods against which to compare myopia treatments. A meta-analysis of  published data on myopia progression in Chinese children with SV spectacles and contact lenses was conducted, data extracted, and a model developed to estimate myopia progression in SV lenses for up to 3 years. This model offers a valid alternative to assigning children to SV lenses in randomized clinical trials and can also be additionally used to demonstrate progression in SV lenses. For a 10-year-old myopic child, progression was estimated at an average of 0.36mm, 0.63mm and 0.84mm after 1, 2 and 3 years of SV⁷.